» Articles » PMID: 32585911

Extracellular Vesicles from Skeletal Muscle Cells Efficiently Promote Myogenesis in Induced Pluripotent Stem Cells

Abstract

The recent advances, offered by cell therapy in the regenerative medicine field, offer a revolutionary potential for the development of innovative cures to restore compromised physiological functions or organs. Adult myogenic precursors, such as myoblasts or satellite cells, possess a marked regenerative capacity, but the exploitation of this potential still encounters significant challenges in clinical application, due to low rate of proliferation in vitro, as well as a reduced self-renewal capacity. In this scenario, induced pluripotent stem cells (iPSCs) can offer not only an inexhaustible source of cells for regenerative therapeutic approaches, but also a valuable alternative for in vitro modeling of patient-specific diseases. In this study we established a reliable protocol to induce the myogenic differentiation of iPSCs, generated from pericytes and fibroblasts, exploiting skeletal muscle-derived extracellular vesicles (EVs), in combination with chemically defined factors. This genetic integration-free approach generates functional skeletal myotubes maintaining the engraftment ability in vivo. Our results demonstrate evidence that EVs can act as biological "shuttles" to deliver specific bioactive molecules for a successful transgene-free differentiation offering new opportunities for disease modeling and regenerative approaches.

Citing Articles

Bioactive Hydrogel Supplemented with Stromal Cell-Derived Extracellular Vesicles Enhance Wound Healing.

Galbiati M, Maiullari F, Ceraolo M, Bousselmi S, Fratini N, Gega K Pharmaceutics. 2025; 17(2).

PMID: 40006529 PMC: 11859224. DOI: 10.3390/pharmaceutics17020162.


Classes of Stem Cells: From Biology to Engineering.

Shah S, Ghosh D, Otsuka T, Laurencin C Regen Eng Transl Med. 2024; 10(3):309-322.

PMID: 39387056 PMC: 11463971. DOI: 10.1007/s40883-023-00317-x.


Extracellular vesicles may provide an alternative detoxification pathway during skeletal muscle myoblast ageing.

Fernandez-Rhodes M, Buchan E, Gagnon S, Qian J, Gethings L, Lees R J Extracell Biol. 2024; 3(8):e171.

PMID: 39169919 PMC: 11336379. DOI: 10.1002/jex2.171.


Defining the influence of size-exclusion chromatography fraction window and ultrafiltration column choice on extracellular vesicle recovery in a skeletal muscle model.

Fernandez-Rhodes M, Adlou B, Williams S, Lees R, Peacock B, Aubert D J Extracell Biol. 2024; 2(4):e85.

PMID: 38939692 PMC: 11080914. DOI: 10.1002/jex2.85.


Mitochondrial mechanisms in the pathogenesis of chronic inflammatory musculoskeletal disorders.

Wu K, Shieh J, Qin L, Guo J Cell Biosci. 2024; 14(1):76.

PMID: 38849951 PMC: 11162051. DOI: 10.1186/s13578-024-01259-9.


References
1.
Charlton C, MOHLER W, Blau H . Neural cell adhesion molecule (NCAM) and myoblast fusion. Dev Biol. 2000; 221(1):112-9. DOI: 10.1006/dbio.2000.9654. View

2.
Romancino D, Paterniti G, Campos Y, De Luca A, Di Felice V, dAzzo A . Identification and characterization of the nano-sized vesicles released by muscle cells. FEBS Lett. 2013; 587(9):1379-84. PMC: 4714929. DOI: 10.1016/j.febslet.2013.03.012. View

3.
Roca I, Requena J, Edel M, Alvarez-Palomo A . Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy. J Clin Med. 2015; 4(2):243-59. PMC: 4470123. DOI: 10.3390/jcm4020243. View

4.
Uchimura T, Otomo J, Sato M, Sakurai H . A human iPS cell myogenic differentiation system permitting high-throughput drug screening. Stem Cell Res. 2017; 25:98-106. DOI: 10.1016/j.scr.2017.10.023. View

5.
Forterre A, Jalabert A, Berger E, Baudet M, Chikh K, Errazuriz E . Proteomic analysis of C2C12 myoblast and myotube exosome-like vesicles: a new paradigm for myoblast-myotube cross talk?. PLoS One. 2014; 9(1):e84153. PMC: 3879278. DOI: 10.1371/journal.pone.0084153. View